Edesa Biotech EV / EBITDA
Mi az Edesa Biotech EV / EBITDA?
A EV / EBITDA az Edesa Biotech, Inc. - N/A
Mi a EV / EBITDA meghatározása?
Az EV / EBITDA a vállalati érték a kamat, az adózás, az értékcsökkenés és az amortizáció előtti eredményekkel elosztva. Ez azt jelenti, hogy mennyire drága egy állomány, és gyakrabban érvényesül a vállalatok közötti összehasonlításnál, mint az ár / nyereség arány. Megméri az árat (vállalati érték formájában), amelyet a befektető fizet a vállalat pénzforgalmának javára (EBITDA formájában).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA a Health Care szektor a NASDAQ-on cégekben a Edesa Biotech -hoz képest
Mit csinál Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
ev / ebitda -hoz hasonló cégek Edesa Biotech
- Bambuser AB (publ) nak EV / EBITDA N/A van
- Nevada Metals nak EV / EBITDA N/A van
- Elys Game Technology nak EV / EBITDA N/A van
- Velodyne Lidar nak EV / EBITDA N/A van
- Blue Sky Alternative Investments nak EV / EBITDA N/A van
- Arix Bioscience plc nak EV / EBITDA N/A van
- Edesa Biotech nak EV / EBITDA N/A van
- Shenzhen Neptunus Interlong Bio-technique nak EV / EBITDA N/A van
- Baumot AG nak EV / EBITDA N/A van
- Discovery Harbour Resources nak EV / EBITDA N/A van
- Guardion Health Sciences Inc nak EV / EBITDA N/A van
- Taronis Fuels nak EV / EBITDA N/A van
- DQ Entertainment (International) nak EV / EBITDA N/A van